SCHEMBL24251133

SCHEMBL24251133

CCCN(CCC)CCc1ccc(NC(=O)c2ccc(C)c(Nc3nccc(-c4cccnc4)n3)c2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 16/20 0.68
ABL1 P00519 9/20 0.68
KIT P10721 8/20 0.68
BCR P11274 6/20 0.66
PDGFRB P09619 6/20 0.66
EGFR P00533 2/20 0.64
PRKCA P17252 1/20 0.64
DDR1 Q08345 2/20 0.62
KDR P35968 2/20 0.62
MAPK8 P45983 2/20 0.61
MAPK9 P45984 2/20 0.61
MAPK10 P53779 2/20 0.61
PLK4 O00444 1/20 0.61
DDX3X O00571 1/20 0.61
GAK O14976 1/20 0.61
SLC22A2 O15244 1/20 0.61
MAPK13 O15264 1/20 0.61
CA12 O43570 1/20 0.61
SLC22A3 O75751 1/20 0.61
ABCB11 O95342 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24251051 0.95 PDGFRA (0.75) PDGFRAABL1KITBCRPDGFRB
SCHEMBL29552117 0.95 PDGFRA (0.75) PDGFRAABL1KITBCRPDGFRB
SCHEMBL24251132 0.94 PDGFRA (0.69) PDGFRAABL1KITBCRPDGFRB
SCHEMBL29551247 0.94 PDGFRA (0.69) PDGFRAABL1KITBCRPDGFRB
SCHEMBL24251131 0.94 PDGFRA (0.69) PDGFRAABL1KITBCRPDGFRB
SCHEMBL29551537 0.91 PDGFRA (0.71) PDGFRAABL1KITBCRPDGFRB
SCHEMBL24251016 0.91 PDGFRA (0.71) PDGFRAABL1KITBCRPDGFRB
SCHEMBL29551463 0.91 ABL1 (0.57) PDGFRAABL1KITBCRPDGFRB
SCHEMBL24251083 0.91 ABL1 (0.57) PDGFRAABL1KITBCRPDGFRB
SCHEMBL24251012 0.90 PDGFRA (0.77) PDGFRAABL1KITBCRPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers HONGYI & ASS LLC (US) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048893-A1 Compounds for Treating Neurodegenerative Diseases and Cancers SNCA, NGF, SLC18A2 PDGFRA 145/4885ABL1 695/4885KIT 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.